MaxCyte Inc
NASDAQ:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sunshine Insurance Group Co Ltd
HKEX:6963
|
CN |
|
RMC Switchgears Ltd
BSE:540358
|
IN |
|
Geomatec Co Ltd
TSE:6907
|
JP |
|
E
|
East Stone Acquisition Corp
NASDAQ:NWTN
|
US |
|
Yangtze Optical Fibre and Cable Joint Stock Ltd Co
SSE:601869
|
CN |
|
C
|
Cosmo Ferrites Ltd
BSE:523100
|
IN |
|
Guangdong Xinhui Meida Nylon Co Ltd
SZSE:000782
|
CN |
MaxCyte Inc
Interest Expense
MaxCyte Inc
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MaxCyte Inc
NASDAQ:MXCT
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Interest Expense
$1.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
Danaher Corp
NYSE:DHR
|
Interest Expense
$265m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Waters Corp
NYSE:WAT
|
Interest Expense
$69.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Interest Expense
$109m
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Interest Expense
$729m
|
CAGR 3-Years
21%
|
CAGR 5-Years
12%
|
CAGR 10-Years
22%
|
|
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
